Ulf Staginnus is VP, Head of Europe Value Demonstration & Access at Shire. He has a long track record in successfully developing launch pricing and market access strategies for various innovative drugs across different therapeutic areas such as oncology, cardiology, infectious diseases and orphan drugs within the top fifteen pharmaceutical companies (Amgen, Novartis, BMS, Pfizer, GSK Biologics) and biotech start-ups (PTC Therapeutics, Endocyte Inc). He is a health economist with almost two decades of international experience in pharmacoeconomics, pricing and reimbursement, as well as competitive intelligence and health technology valuations within the biotechnology and pharmaceutical industry. In 1996, Ulf graduated as Diplom Volkswirt (MA Economics) from the University of Bayreuth, Germany. During the course of his career he also founded and run his own consultancy serving biotech and pharma clients in supporting their product pricing, valuations and market access initiatives.
Ulf is a regular speaker on pricing and health economics related matters. He co-edited a book ‘The Future of Health Economics’ and also contributed to various articles and authored book chapters on strategy and tactics of pharmaceutical pricing and health economics.